Title:Cytotoxicity Evaluation of Dimethoxy and Trimethoxy Indanonic Spiroisoxazolines Against Cancerous Liver Cells
VOLUME: 14 ISSUE: 1
Author(s):Ahmad Abolhasani , Fatemeh Heidari , Somayeh Noori, Shokoufeh Mousavi and Hoda Abolhasani *
Affiliation:Cellular and Molecular Research Center, Qom University of Medical Sciences, Qom, Cellular and Molecular Research Center, Qom University of Medical Sciences, Qom, Cellular and Molecular Research Center, Qom University of Medical Sciences, Qom, Cellular and Molecular Research Center, Qom University of Medical Sciences, Qom, Cellular and Molecular Research Center, Qom University of Medical Sciences, Qom
Keywords:Anticancer, indanonic spiroisoxazoline, HepG2, antitubulin, selective COX-2 inhibitor, cancerous
liver cells.
Abstract:
Background: 3'-(3,4-dimethoxyphenyl)-4'-(4-(methylsulfonyl)phenyl)-4'H-spiro
[indene-2,5'-isoxazol]-1(3H)-one and 4'-(4-(methylsulfonyl)phenyl)-3'-(3,4,5-trimethoxyphenyl)-
4'H-spiro[indene-2,5'-isoxazol]-1(3H)-one compounds containing indanonic spiroisoxazoline
core are widely known for their antiproliferative activities and investigation of
tubulin binding modes.
Objective: To evaluate the cytotoxicity effect of Dimethoxy and Trimethoxy Indanonic Spiroisoxazolines
against HepG2 cancerous liver cell line and to perform a comparison with
other known anti-liver cancer drugs.
Methods: The evaluation of cytotoxicity of dimethoxy and trimethoxy indanonic spiroisoxazoline
compounds, Oxaliplatin, Doxorubicin, 5-fluorouracil and Cisplatin against HepG2
(hepatocellular liver carcinoma) cell line has been performed using MTT assay and analyzed
by GraphPad PRISM software (version 8.0.2).
Results: Potent cytotoxicity effects against HepG2 cell line, comparable to Cisplatin (IC50=
0.047±0.0045 µM), Oxaliplatin (IC50= 0.0051µM), Doxorubicin (IC50= 0.0014µM) and 5-
fluorouracil (IC50= 0.0089 µM), were shown by both dimethoxy (IC50= 0.059±0.012 µM)
and trimethoxy (IC50= 0.086±0.019 µM) indanonic spiroisoxazoline compounds.
Conclusion: In vitro biological evaluations revealed that dimethoxy and trimethoxy indanonic
spiroisoxazoline compounds are good candidates for the development of new anti-liver
cancer agents.